2 results
Approved WMORecruiting
To determine the effect on lower urinary tract symptoms and to determine urodynamic and histologic changes after intraprostatic botulinum toxin type A injection.
Approved WMORecruiting
To determine the objective response rate of entrectinib, as assessed by BICR, in each patient population basket of solid tumors that harbor anNTRK1/2/3, ROS1, or ALK gene rearrangement